| Literature DB >> 32913396 |
Qian Li1,2,3, Mingrui Yuan1,2,3, Xiaohui Li1,2,3, Jinyu Li1,2,3, Ming Xu1,2,3, Di Wei1,2,3, Desong Wu1,2,3, Jinfu Wan1,2,3, Shuangxi Mei1,2,3, Tao Cui1,2,3, Jingkun Wang1,2,3, Zhaoyun Zhu1,2,3.
Abstract
BACKGROUND: Panax notoginseng saponin (PNS) is the extraction from the roots and rhizomes of Panax notoginseng (Burk.) F. H. Chen. PNS is the main bioactive component of Xuesaitong, Xueshuantong, and other Chinese patent medicines, which are all bestselling prescriptions in China to treat cardiocerebrovascular diseases. Notoginsenoside R1 and ginsenoside Rg1, Rd, Re, and Rb1 are the principal effective constituents of PNS, but a systematic research on the rare saponin compositions has not been conducted.Entities:
Keywords: Cytotoxicity; Fingerprint; New dammarane-type triterpenoid saponins; Panax Notoginseng saponins
Year: 2018 PMID: 32913396 PMCID: PMC7471129 DOI: 10.1016/j.jgr.2018.12.001
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Fig. 1The structure of the Compounds 1–28. Glc, β-D-glucopyranosyl; Xyl, β-D-xylopyranosyl; Ara, α-L-arabinofuranosyl; Rha, α-L-rhamnopyranose.
1H [ δ in ppm, multiplicity (J in Hz)] and 13C NMR (δ in ppm) spectroscopic data of Compounds 1–3.1)
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| 1 | 39.9 | 1.70 (1H, m) | 39.7 | 1.65 (1H, m) | 40.0 | 1.71 (1H, m) |
| 2 | 28.4 | 1.94 (1H, m) | 28.2 | 1.91 (1H, m) | 28.4 | 1.95 (1H, m) |
| 3 | 79.0 | 3.55 (1H, m) | 78.7 | 3.52 (1H, m) | 79.0 | 3.55 (1H, m) |
| 4 | 40.9 | 40.7 | 40.9 | |||
| 5 | 61.8 | 1.46 (1H, m) | 61.7 | 1.43 (1H, m) | 61.9 | 1.46 (1H, m) |
| 6 | 80.5 | 4.46 (1H, m) | 80.2 | 4.45 (1H, m) | 80.6 | 4.45 (1H, m) |
| 7 | 45.8 | 2.59 (1H, m) | 45.6 | 2.57 (1H, m) | 45.8 | 2.55 (1H, m) |
| 8 | 41.7 | 41.5 | 41.7 | |||
| 9 | 51.1 | 1.59 (1H, m) | 50.9 | 1.59 (1H, m) | 51.1 | 1.58 (1H, m) |
| 10 | 40.1 | 40.0 | 40.2 | |||
| 11 | 32.7 | 1.50 (2H, m) | 32.8 | 1.88 (1H, m) | 31.5 | 1.98 (1H, m) |
| 12 | 80.2 | 4.29 (1H, m) | 80.0 | 4.25 (1H, m) | 80.2 | 4.28 (1H, m) |
| 13 | 59.1 | 2.13 (1H, m) | 55.4 | 2.29 (1H, m) | 52.8 | 2.16 (1H, m) |
| 14 | 52.2 | 51.7 | 51.6 | |||
| 15 | 33.4 | 1.92 (1H, m) | 32.9 | 1.52 (1H, m) | 33.0 | 1.76 (1H, m) |
| 16 | 34.7 | 2.16 (1H, m) | 35.9 | 2.21 (1H, m) | 35.1 | 2.18 (1H, m) |
| 17 | 40.2 | 3.05 (1H, m) | 38.4 | 2.91 (1H, m) | 48.7 | 2.29 (1H, m) |
| 18 | 17.8 | 1.25 (3H, s) | 17.6 | 1.28 (3H, s) | 17.8 | 1.24 (3H, s) |
| 19 | 18.2 | 1.04 (3H, s) | 18.1 | 1.03 (3H, s) | 18.2 | 1.05 (3H, s) |
| 20 | 160.2 | 156.3 | 156.5 | |||
| 21 | 111.2 | 5.31 (2H, d, | 113.9 | 5.29 (2H, d, | 108.4 | 5.15 (1H, s) |
| 22 | 77.0 | 4.52 (1H, m) | 91.3 | 4.71 (1H, t, | 33.1 | 2.77 (1H, m) |
| 23 | 36.3 | 2.73 (1H, m) | 31.3 | 2.60 (1H, m) | 33.2 | 2.06 (1H, m) |
| 24 | 122.4 | 5.42 (1H, t, | 121.1 | 5.34 (1H, t, | 75.5 | 4.46 (1H, m) |
| 25 | 132.8 | 133.4 | 150.0 | |||
| 26 | 26.4 | 1.71 (3H, s) | 26.1 | 1.65 (3H, s) | 110.5 | 5.29 (1H, s) |
| 27 | 18.6 | 1.65 (3H, s) | 18.3 | 1.59 (3H, s) | 18.7 | 1.91 (3H, s) |
| 28 | 32.2 | 2.10 (3H, s) | 32.0 | 2.08 (3H, s) | 32.2 | 2.10 (3H, s) |
| 29 | 16.8 | 1.63 (3H, s) | 16.7 | 1.60 (3H, s) | 16.8 | 1.63 (3H, s) |
| 30 | 17.1 | 0.88 (3H, s) | 16.9 | 0.82 (3H, s) | 17.2 | 0.82 (3H, s) |
| 6-O-sugar | ||||||
| 1 | 106.5 | 5.07 (1H, d, | 106.3 | 5.04 (1H, d, | 106.4 | 5.05 (1H, d, |
| 2 | 73.0 | 3.99 (1H, m) | 73.2 | 3.93 (1H, m) | 73.0 | 3.91 (1H, m) |
| 3 | 78.7 | 3.99 (1H, m) | 78.5 | 3.96 (1H, m) | 78.6 | 3.98 (1H, m) |
| 4 | 72.3 | 4.26 (1H, m) | 72.1 | 4.22 (1H, m) | 72.3 | 4.27 (1H, m) |
| 5 | 75.9 | 4.13 (1H, m) | 75.7 | 4.10 (1H, m) | 75.9 | 4.13 (1H, m) |
| 6 | 63.5 | 4.57 (1H, m) | 63.4 | 4.54 (1H, m) | 63.5 | 4.54 (1H, m) |
NMR, nuclear magnetic resonance; s, singlet; d,doublet; t, triplet; m, multiplet
Measured in pyridine-d, 500 MHz for 1H, 125 MHz for 13C, The assignment was based on DEPT, correalation spectroscopy (COSY), HSQC, and HMBC experiments.
Fig. 2The important HMBC correlations of Compounds 1–3. HMBC, heteronuclear multiplebond correlation.
Fig. 3(A) The HPLC fingerprint of PNS. (B) The magnified HPLC fingerprint of PNS with compounds isolated from PNS marked. (1, notoginsenoside Ab1; 2, notoginsenoside Ab3; 3, notoginsenoside Ab3; 4, notoginsenoside R2; 5, 20(S)-ginsenoside Rh1; 6, 20(S)-ginsenoside Rg2; 7, ginsenoside Rg3; 8, pseudoginsenoside RT3; 9, gypenoside-XVII; 10, vina-ginsenoside-R4; 11, notoginsenoside R3; 12, quinquenoside L14; 13, 20(R)-ginsenoside Rh1; 14, ginsenoside F2; 15, ginsenoside U; 16, ginsenoside Rg6; 17, ginsenoside Rk3; 18, notoginsenoside T5; 19, ginsenoside RK120, ginsenoside Rg4; 21, ginsenoside-Rh4; 22, ginsenoside-Rh5; 23, 20(S)-ginsenoside-ST2; 24, floralquinquenoside A; 25, ginsenoside-Rh14; 26, notopanaxoside A; 27, notopanaxoside G; 28, sanchirhinoside D). All the Compounds 1-28 isolated form PNS and the sample of PNS were analysis by HPLC at the same condition. In addition, 1-28 were marked on the HPLC spectrum of PNS.
IC50 values of the new Compounds (1–3) against HepG2, NCI-H460, and MCF-7 cells.
| Comp. | IC50 (μg/mL) | ||
|---|---|---|---|
| HepG2 | NCI-H460 | MCF-7 | |
| >100 | >100 | >100 | |
| 4.49 | 8.06 | 7.38 | |
| >100 | >100 | >100 | |
| Cisplatin | 0.97 | 1.34 | 2.66 |
Cell inhibition activity was determined by the MTT assay. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide
IC50 is the concentration of the compound inhibiting 50% of cell proliferation.
Cisplatin was used as positive control.